Education:

1981-1985 B.S., Zoology, Nanjing University, China
1985-1988 M.S., Zoology, Nanjing University, China
1995-1998 Ph.D., Molecular Biology, Sun Yat-sen University, China
2001-2003 Cancer Biology, George Whipple Cancer Lab, University of Rochester, USA
2003-2007 Cancer Biology, MD Anderson Cancer Center, USA

Professional Experience:

1998-2001 Associate Investigator, Sun Yat-sen University
2008-2010 Research Fellow, MD Anderson Cancer Center, USA
2010- Present Professor, Cyrus Tang Hematology Center, Soochow University, China
2011- Present Adjunct Professor, MD Anderson Cancer Center, USA

Research:

Investigators:

Gangli An, M.S., Senior Research Associate
Huimin Meng, M.S., Senior Research Associate
Xinding Zhang, Ph.D., Postdoctoral Fellow
Jianxuan Zou, Ph.D. Student
Jinle Tang, Ph.D. Student
Yunhui Zong, Master Student
Lei Huang, Master Student
Jialu Li, Master Student
Licui Jiang, Master Student
Lifen Li, Master Student
Dan Chen, Master Student

Representative Publications:

1. Ma R, You F, Tian S, Zhang T, Tian X, Xiang S, Wu H, Yang N, An G, Yang L. Enhanced efficacy of CD19/CD22 bispecific CAR-T cells with EAAAK linker on B-cell malignancies. Eur J Haematol. 2023 Sep 6. doi: 10.1111/ejh.14090. Epub ahead of print. PMID: 37671595.

2. Wang T, Zhang K, You F, Ma R, Yang N, Tian S, An G, Yang L. Preconditioning of radiotherapy enhances efficacy of B7-H3-CAR-T in treating solid tumor models. Life Sci. 2023 Oct 15;331:122024. doi: 10.1016/j.lfs.2023.122024. Epub 2023 Aug 12. PMID: 37574043.

3. Sheng B, Zhang K, Tian S, Ma R, Li Z, Wu H, Wang T, Jiang L, You F, An G, Meng H, Yang L, Liu X. CD7 protein plays a crucial role in T cell infiltration in tumors. Heliyon. 2023 Jun 15;9(6):e16961. doi: 10.1016/j.heliyon.2023.e16961. PMID: 37416646; PMCID: PMC10320036.

4. Fan S, Wang T, You F, Zhang T, Li Y, Ji C, Han Z, Sheng B, Zhai X, An G, Meng H, Yang L. B7-H3 chimeric antigen receptor-modified T cell shows potential for targeted treatment of acute myeloid leukaemia. Eur J Med Res. 2023 Mar 20;28(1):129. doi: 10.1186/s40001-023-01049-y. PMID: 36941687; PMCID: PMC10026503.

5. Cao X, Dai H, Cui Q, Li Z, Shen W, Pan J, Shen H, Ma Q, Li M, Chen S, Chen J, Zhu X, Meng H, Yang L, Wu D, Tang X. CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia. Exp Hematol Oncol. 2022 Sep 29;11(1):67. doi: 10.1186/s40164-022-00318-6. PMID: 36175988; PMCID: PMC9523980.

6. Li Z, Zhou Z, Tian S, Zhang K, An G, Zhang Y, Ma R, Sheng B, Wang T, Yang H, Yang L. RPRM deletion preserves hematopoietic regeneration by promoting EGFR-dependent DNA repair and hematopoietic stem cell proliferation post ionizing radiation. Cell Biol Int. 2022 Dec;46(12):2158-2172. doi: 10.1002/cbin.11900. Epub 2022 Aug 30. PMID: 36041213; PMCID: PMC9804513.

7. Liu Z, Li X, Li X, Li Z, Chen H, Gong S, Zhang M, Zhang Y, Li Z, Yang L, Liu H. The kidney-expressed transcription factor ZKSCAN3 is dispensable for autophagy transcriptional regulation and AKI progression in mouse. Mutat Res. 2022 Jul-Dec;825:111790. doi: 10.1016/j.mrfmmm.2022.111790. Epub 2022 Jul 9. PMID: 35841832.

8. Zhang M, Chen D, Fu X, Meng H, Nan F, Sun Z, Yu H, Zhang L, Li L, Li X, Wang X, Wang M, You F, Li Z, Chang Y, Zhou Z, Yan J, Li J, Wu X, Wang Y, Wang Y, Xiang S, Chen Y, Pan G, Xu H, Zhang B, Yang L. Autologous Nanobody-Derived Fratricide-Resistant CD7-CAR T-cell Therapy for Patients with Relapsed and Refractory T-cell Acute Lymphoblastic Leukemia/Lymphoma. Clin Cancer Res. 2022 Jul 1;28(13):2830-2843. doi: 10.1158/1078-0432.CCR-21-4097. PMID: 35435984.

9. Dai HP, Cui W, Cui QY, Zhu WJ, Meng HM, Zhu MQ, Zhu XM, Yang L, Wu DP, Tang XW. Haploidentical CD7 CAR T-cells induced remission in a patient with TP53 mutated relapsed and refractory early T-cell precursor lymphoblastic leukemia/lymphoma. Biomark Res. 2022 Feb 7;10(1):6. doi: 10.1186/s40364-022-00352-w. PMID: 35130959; PMCID: PMC8822664.

10. Zhang T, Wang T, You F, Li Z, Chen D, Zhang K, Tian S, Sheng B, Wu H, Jiang L, Ma R, An G, Meng H, Yang L. Nanobody-based anti-CD22-chimeric antigen receptor T cell immunotherapy exhibits improved remission against B-cell acute lymphoblastic leukemia. Transpl Immunol. 2022 Apr;71:101538. doi: 10.1016/j.trim.2022.101538. Epub 2022 Jan 18. PMID: 35051588.

11. Li Z, Sheng B, Zhang T, Wang T, Chen D, An G, Wang X, Meng H, Yang L. Zkscan3 affects erythroblast development by regulating the transcriptional activity of GATA1 and KLF1 in mice. J Mol Histol. 2022 Apr;53(2):423-436. doi: 10.1007/s10735-021-10052-8. Epub 2021 Dec 23. PMID: 34940950; PMCID: PMC9117376.

12. Chen D, You F, Xiang S, Wang Y, Li Y, Meng H, An G, Zhang T, Li Z, Jiang L, Wu H, Sheng B, Zhang B, Yang L. Chimeric antigen receptor T cells derived from CD7 nanobody exhibit robust antitumor potential against CD7-positive malignancies. Am J Cancer Res. 2021 Nov 15;11(11):5263-5281. PMID: 34873460; PMCID: PMC8640809.

13. Zhai X, You F, Xiang S, Jiang L, Chen D, Li Y, Fan S, Han Z, Zhang T, An G, Zhang B, Chen Y, Meng H, Yang L. MUC1-Tn-targeting chimeric antigen receptor-modified Vγ9Vδ2 T cells with enhanced antigen-specific anti-tumor activity. Am J Cancer Res. 2021 Jan 1;11(1):79-91. PMID: 33520361; PMCID: PMC7840711.

14. You F, Wang Y, Jiang L, Zhu X, Chen D, Yuan L, An G, Meng H, Yang L. A novel CD7 chimeric antigen receptor-modified NK-92MI cell line targeting T-cell acute lymphoblastic leukemia. Am J Cancer Res. 2019 Jan 1;9(1):64-78. PMID: 30755812; PMCID: PMC6356925.

15. Zhang P, Zhao S, Wu C, Li J, Li Z, Wen C, Hu S, An G, Meng H, Zhang X, Yang L. Effects of CSF1R-targeted chimeric antigen receptor-modified NK92MI & T cells on tumor-associated macrophages. Immunotherapy. 2018 Aug;10(11):935-949. doi: 10.2217/imt-2018-0012. PMID: 30149762.

16. Tang X, Yang L, Li Z, Nalin AP, Dai H, Xu T, Yin J, You F, Zhu M, Shen W, Chen G, Zhu X, Wu D, Yu J. First-in-man clinical trial of CAR NK-92 cells: safety test of CD33-CAR NK-92 cells in patients with relapsed and refractory acute myeloid leukemia. Am J Cancer Res. 2018 Jun 1;8(6):1083-1089. Erratum in: Am J Cancer Res. 2018 Sep 01;8(9):1899. PMID: 30034945; PMCID: PMC6048396.

17. Meng H, Sun X, Song Y, Zou J, An G, Jin Z, Yang L. La/SSB chimeric autoantibody receptor modified NK92MI cells for targeted therapy of autoimmune disease. Clin Immunol. 2018 Jul;192:40-49. doi: 10.1016/j.clim.2018.04.006. Epub 2018 Apr 16. PMID: 29673902.

18. Wang H, Baladandayuthapani V, Wang Z, Lin H, Berkova Z, Davis RE, Yang L, Orlowski RZ. Truncated protein tyrosine phosphatase receptor type O suppresses AKT signaling through IQ motif containing GTPase activating protein 1 and confers sensitivity to bortezomib in multiple myeloma. Oncotarget. 2017 Dec 7;8(69):113858-113873. doi: 10.18632/oncotarget.23017. PMID: 29371952; PMCID: PMC5768369.

19. Chen Y, You F, Jiang L, Li J, Zhu X, Bao Y, Sun X, Tang X, Meng H, An G, Zhang B, Yang L. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody. Oncotarget. 2017 Jun 6;8(23):37128-37139. doi: 10.18632/oncotarget.16201. PMID: 28415754; PMCID: PMC5514896.

20. Yu Y, Li J, Zhu X, Tang X, Bao Y, Sun X, Huang Y, Tian F, Liu X, Yang L. Humanized CD7 nanobody-based immunotoxins exhibit promising anti-T-cell acute lymphoblastic leukemia potential. Int J Nanomedicine. 2017 Mar 13;12:1969-1983. doi: 10.2147/IJN.S127575. PMID: 28331319; PMCID: PMC5357075.

21. Zhang XD, Baladandayuthapani V, Lin H, Mulligan G, Li B, Esseltine DW, Qi L, Xu J, Hunziker W, Barlogie B, Usmani SZ, Zhang Q, Crowley J, Hoering A, Shah JJ, Weber DM, Manasanch EE, Thomas SK, Li BZ, Wang HH, Zhang J, Kuiatse I, Tang JL, Wang H, He J, Yang J, Milan E, Cenci S, Ma WC, Wang ZQ, Davis RE, Yang L, Orlowski RZ. Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling. Cancer Cell. 2016 May 9;29(5):639-652. doi: 10.1016/j.ccell.2016.03.026. Epub 2016 Apr 28. PMID: 27132469; PMCID: PMC4983190.

22. Tang J, Li J, Zhu X, Yu Y, Chen D, Yuan L, Gu Z, Zhang X, Qi L, Gong Z, Jiang P, Yu J, Meng H, An G, Zheng H, Yang L. Novel CD7-specific nanobody-based immunotoxins potently enhanced apoptosis of CD7-positive malignant cells. Oncotarget. 2016 Jun 7;7(23):34070-83. doi: 10.18632/oncotarget.8710. PMID: 27083001; PMCID: PMC5085138.

23. You F, Jiang L, Zhang B, Lu Q, Zhou Q, Liao X, Wu H, Du K, Zhu Y, Meng H, Gong Z, Zong Y, Huang L, Lu M, Tang J, Li Y, Zhai X, Wang X, Ye S, Chen D, Yuan L, Qi L, Yang L. Phase 1 clinical trial demonstrated that MUC1 positive metastatic seminal vesicle cancer can be effectively eradicated by modified Anti-MUC1 chimeric antigen receptor transduced T cells. Sci China Life Sci. 2016 Apr;59(4):386-97. doi: 10.1007/s11427-016-5024-7. Epub 2016 Mar 7. PMID: 26961900.

24. Chen D, Zou J, Zong Y, Meng H, An G, Yang L. Anti-human CD138 monoclonal antibodies and their bispecific formats: generation and characterization. Immunopharmacol Immunotoxicol. 2016 Jun;38(3):175-83. doi: 10.3109/08923973.2016.1153110. Epub 2016 Mar 8. PMID: 26954291.

25. Zou J, Chen D, Zong Y, Ye S, Tang J, Meng H, An G, Zhang X, Yang L. Immunotherapy based on bispecific T-cell engager with hIgG1 Fc sequence as a new therapeutic strategy in multiple myeloma. Cancer Sci. 2015 May;106(5):512-21. doi: 10.1111/cas.12631. Epub 2015 Mar 13. PMID: 25664501; PMCID: PMC4452151.